GlassScriptPhysician profile
Howard Henry Farrington
NPI 1538268354
$13,910.94
in general payments reported to CMS, 2019-2025
50 companies · $981 in 2025
The $981 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,787 · 2020: $1,689 · 2021: $1,903 · 2022: $2,263 · 2023: $2,371 · 2024: $2,918 · 2025: $981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,164 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,163.63 |
| Education | $105.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,131.77 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $1,940.19 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $1,328.07 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $1,316.19 | 2019-2025 | |
| Pfizer INC. | $1,118.10 | 2019-2025 | |
| Lilly USA, LLC | $1,115.46 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $518.86 | 2019-2025 | Jardiance, Stiolto Respimat |
| Teva Pharmaceuticals USA, INC. | $500.43 | 2020-2025 | Austedo Xr, Austedo Xr |
| Bayer Healthcare Pharmaceuticals INC. | $383.15 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $268.62 | 2019-2024 | Vaxelis, Gardasil 9, Gardasil |
| Allergan, INC. | $233.15 | 2019-2020 | |
| Amarin Pharma, INC. | $230.83 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $203.79 | 2019-2023 | Qelbree |
| Amgen INC. | $196.09 | 2019-2025 | Otezla, Repatha, Otezla |
| Exact Sciences Corporation | $195.97 | 2023-2025 | Cologuard Collection Kit |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Farrington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.